JP2007513873A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513873A5
JP2007513873A5 JP2006536183A JP2006536183A JP2007513873A5 JP 2007513873 A5 JP2007513873 A5 JP 2007513873A5 JP 2006536183 A JP2006536183 A JP 2006536183A JP 2006536183 A JP2006536183 A JP 2006536183A JP 2007513873 A5 JP2007513873 A5 JP 2007513873A5
Authority
JP
Japan
Prior art keywords
polypeptide
agent
antibody
expression
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536183A
Other languages
English (en)
Japanese (ja)
Other versions
JP4764344B2 (ja
JP2007513873A (ja
Filing date
Publication date
Priority claimed from GB0324656A external-priority patent/GB0324656D0/en
Application filed filed Critical
Publication of JP2007513873A publication Critical patent/JP2007513873A/ja
Publication of JP2007513873A5 publication Critical patent/JP2007513873A5/ja
Application granted granted Critical
Publication of JP4764344B2 publication Critical patent/JP4764344B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536183A 2003-10-22 2004-10-22 卵巣癌に関与するタンパク質 Expired - Fee Related JP4764344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0324656A GB0324656D0 (en) 2003-10-22 2003-10-22 A protein involved in ovarian cancer
GB0324656.8 2003-10-22
PCT/GB2004/004502 WO2005042102A1 (en) 2003-10-22 2004-10-22 A protein involved in ovarian cancer

Publications (3)

Publication Number Publication Date
JP2007513873A JP2007513873A (ja) 2007-05-31
JP2007513873A5 true JP2007513873A5 (https=) 2007-10-18
JP4764344B2 JP4764344B2 (ja) 2011-08-31

Family

ID=29595617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536183A Expired - Fee Related JP4764344B2 (ja) 2003-10-22 2004-10-22 卵巣癌に関与するタンパク質

Country Status (11)

Country Link
US (3) US20070009543A1 (https=)
EP (1) EP1677875B1 (https=)
JP (1) JP4764344B2 (https=)
AT (1) ATE470478T1 (https=)
AU (1) AU2004285339B2 (https=)
CA (1) CA2541846A1 (https=)
DE (1) DE602004027647D1 (https=)
ES (1) ES2347249T3 (https=)
GB (1) GB0324656D0 (https=)
PL (1) PL1677875T3 (https=)
WO (1) WO2005042102A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20090274619A1 (en) * 2006-01-26 2009-11-05 George Coukos Tumor vasculature markers and methods of use therof
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US8664358B2 (en) * 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗cdcp1抗體
ES2689668T3 (es) 2013-03-13 2018-11-15 Nantenergy, Inc. Aditivos sinérgicos para celdas electroquímicas con combustible electrodepositado
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
EP4055058A4 (en) * 2019-11-06 2023-12-06 Commonwealth Scientific and Industrial Research Organisation BINDING OF PROTEINS TO THE DOMAIN CONTAINING PROTEIN (CDCP1)
CN118459596A (zh) 2019-12-27 2024-08-09 凯奥目生物科学株式会社 抗cdcp1抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002004508A1 (de) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
CA2787820A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycoprotein antigen sima135 expressed in metastatic human tumor cells

Similar Documents

Publication Publication Date Title
JP6100822B2 (ja) プロカルシトニンの検出のためのイムノアッセイ
JP2021167805A (ja) SARS−CoV−2感染症を診断するための方法および試薬
EP2828282B1 (en) Biomarkers
JP2007513873A5 (https=)
JP2014506244A5 (https=)
JP2012515226A5 (https=)
JP2009544284A5 (https=)
Okochi et al. Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody
JP2011501946A5 (https=)
Lévêque et al. Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism
US7842456B2 (en) Reagents, kits and methods for immunodetection of epitopes on molecules
RU2019113127A (ru) REP белок в качестве белкового антигена для диагностических анализов
EP2332988A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
JP2005522228A5 (https=)
JP2021528411A5 (https=)
Snitkoff et al. Development of an immunoassay for monitoring the levels of ciprofloxacin patient samples
JP2012503634A5 (https=)
WO2020252394A2 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
JP2008509082A5 (https=)
JPWO2024090571A5 (https=)
JP2005522229A5 (https=)
Morrissey et al. Kinetics of antigen− antibody interactions employing a MALDI mass spectrometry immunoassay
CA2771954A1 (en) Pneumonia biomarkers
JP2014520825A5 (https=)
US10094833B2 (en) Method and kit for detecting bacterial infection